Discover how the protein calprotectin could unlock new understanding in the fight against hypertension, a silent threat lurking in our bloodstream.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Plasma Calprotectin Levels Associate With New-Onset Hypertension in the General Population: A Prospective Cohort Study.
Bourgonje et al., J Am Heart Assoc 2023
DOI: 10.1161/JAHA.123.031458
What’s New: This study identifies plasma calprotectin, a marker of neutrophil-mediated inflammation, as a potential biomarker for the risk of developing new-onset hypertension in the general population.
Importance: Understanding the role of inflammation in hypertension can help in early identification and prevention strategies.
Contribution to Literature: The study adds to the evidence linking systemic inflammation to hypertension and highlights sex and urinary albumin excretion as modifiers of this association.
Results Summary: Among 3524 participants without initial hypertension, median plasma calprotectin was 0.48 mg/L, and systolic blood pressure was 117 mm Hg. Calprotectin levels were significantly associated with new-onset hypertension risk (hazard ratio [HR] per doubling of calprotectin: 1.30; P<0.001). This association remained after adjusting for age and sex (HR: 1.26; P<0.001), but not after adjusting for baseline systolic blood pressure and other factors (HR: 1.00; P=0.996). The risk was higher in men and those with higher urinary albumin excretion.